$CRKN
Crown Electrokinetics Corp. Stock $crkn

$crkn Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023025483 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$22.00K	$0.00	$0.00
YoY Change
Cost Of Revenue	$31.00K
YoY Change
Gross Profit	-$9.000K		$0.00
YoY Change
Gross Profit Margin	-40.91%
Selling, General & Admin	$3.576M	$2.367M	$11.00M
YoY Change	3.03%	-47.86%	-23.43%
% of Gross Profit
Research & Development	$541.0K	$584.0K	$4.107M
YoY Change	-50.64%	-54.2%	64.54%
% of Gross Profit
Depreciation & Amortization	$128.0M	$143.0K	$46.00K
YoY Change	119526.17%	64.37%	-79.56%
% of Gross Profit
Operating Expenses	$4.117M	$2.951M	$15.11M
YoY Change	-9.85%	-49.25%	-10.41%
Operating Profit	-$4.126M		-$15.11M
YoY Change	-9.66%
Interest Expense	$2.017M	-$150.0K	$7.000K
YoY Change	-67333.33%	4900.0%	-200.0%
% of Operating Profit
Other Income/Expense, Net	$1.826M	$949.0K	$793.0K
YoY Change	-60966.67%	-15916.67%	-1541.82%
Pretax Income	-$2.300M	-$2.152M	-$14.32M
YoY Change	-49.67%	-60.04%	-13.17%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$2.300M	-$2.184M	-$14.32M
YoY Change	-49.67%	-59.45%	-13.17%
Net Earnings / Revenue	-10454.55%
Basic Earnings Per Share	-$4.88		-$0.82
Diluted Earnings Per Share	-$0.08	-$0.11	-$0.82
COMMON SHARES
Basic Shares Outstanding	43.69M shares	20.24M shares	17.44M shares
Diluted Shares Outstanding	29.70M shares		17.44M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.138M	$821.0K	$821.0K
YoY Change	-14.92%	-86.61%	-86.61%
Cash & Equivalents	$2.138M	$821.0K	$821.0K
Short-Term Investments
Other Short-Term Assets	$97.00K	$63.00K	$590.0K
YoY Change	-87.47%	-90.83%	-14.12%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$2.861M	$1.411M	$1.411M
YoY Change	-12.96%	-79.3%	-79.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.528M	$1.409M	$3.251M
YoY Change	-17.63%	57.43%	263.24%
Goodwill	$652.0K
YoY Change
Intangibles	$1.744M	$1.598M
YoY Change		-9.26%
Long-Term Investments
YoY Change
Other Assets	$213.0K	$180.0K	$330.0K
YoY Change	-47.01%	0.56%	84.36%
Total Long-Term Assets	$15.11M	$5.179M	$5.179M
YoY Change	191.3%	82.68%	82.68%
TOTAL ASSETS
Total Short-Term Assets	$2.861M	$1.411M	$1.411M
Total Long-Term Assets	$15.11M	$5.179M	$5.179M
Total Assets	$17.97M	$6.590M	$6.590M
YoY Change	112.06%	-31.72%	-31.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.146M	$865.0K	$865.0K
YoY Change	247.27%	141.62%	141.62%
Accrued Expenses	$230.0K	$621.0K	$1.195M
YoY Change	-61.47%	108.39%	301.01%
Deferred Revenue
YoY Change
Short-Term Debt	$4.710M	$1.662M	$1.662M
YoY Change	58775.0%	20675.0%	20675.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.016M	$4.694M	$4.694M
YoY Change	864.28%	606.93%	606.93%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.208M	$1.366M	$1.366M
YoY Change	-33.41%
Total Long-Term Liabilities	$1.208M	$1.366M	$1.366M
YoY Change	-33.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.016M	$4.694M	$4.694M
Total Long-Term Liabilities	$1.208M	$1.366M	$1.366M
Total Liabilities	$10.22M	$6.060M	$6.060M
YoY Change	271.92%	812.65%	812.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$90.31M	-$88.01M
YoY Change		19.43%
Common Stock	$4.000K	$2.000K
YoY Change		100.0%
Preferred Stock	$4.350M
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.744M	$530.0K	$530.0K
YoY Change
Total Liabilities & Shareholders Equity	$17.97M	$6.590M	$6.590M
YoY Change	112.06%	-31.72%	-31.72%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.300M	-$2.184M	-$14.32M
YoY Change	-49.67%	-59.45%	-13.17%
Depreciation, Depletion And Amortization	$128.0M	$143.0K	$46.00K
YoY Change	119526.17%	64.37%	-79.56%
Cash From Operating Activities	-$4.728M	-$3.091M	-$11.14M
YoY Change	33.11%	-6.36%	30.49%
INVESTING ACTIVITIES
Capital Expenditures	$435.0K	$473.0K	$812.0K
YoY Change	-769.23%	-275.19%	-199.51%
Acquisitions
YoY Change
Other Investing Activities	-$645.0K
YoY Change
Cash From Investing Activities	-$1.080M	-$473.0K	-$812.0K
YoY Change	1561.54%	75.19%	-0.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$855.0K
YoY Change			359.68%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$7.125M	4.043M	$6.643M
YoY Change			3471.51%
NET CHANGE
Cash From Operating Activities	-$4.728M	-3.091M	-$11.14M
Cash From Investing Activities	-$1.080M	-473.0K	-$812.0K
Cash From Financing Activities	$7.125M	4.043M	$6.643M
Net Change In Cash	$1.317M	479.0K	-$5.309M
YoY Change		-113.41%	-42.09%
FREE CASH FLOW
Cash From Operating Activities	-$4.728M	-$3.091M	-$11.14M
Capital Expenditures	$435.0K	$473.0K	$812.0K
Free Cash Flow	-$5.163M	-$3.564M	-$11.95M
YoY Change	48.06%	17.58%	54.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	333-249833
CY2022	dei	Entity Registrant Name EntityRegistrantName	Crown Electrokinetics Corp.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5423944
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1110 NE Circle Blvd
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Corvallis
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	OR
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	97330
CY2022	dei	City Area Code CityAreaCode	(800)
CY2022	dei	Local Phone Number LocalPhoneNumber	674-3612
CY2022	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.0001 Per Share
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	11300000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43686623	shares
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Name AuditorName	Marcum LLP
CY2022	dei	Auditor Location AuditorLocation	Costa Mesa, California
CY2022Q4	us-gaap	Cash Cash	821000	usd
CY2021Q4	us-gaap	Cash Cash	6130000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	590000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	687000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1411000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	6817000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1409000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	895000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1598000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1761000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1842000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	150000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	180000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	179000	usd
CY2022Q4	us-gaap	Assets Assets	6590000	usd
CY2021Q4	us-gaap	Assets Assets	9652000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	865000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	358000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	621000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	298000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	574000	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	972000	usd
CY2022Q4	crkn	Notes Payable At Fair Value NotesPayableAtFairValue	1654000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	8000	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	8000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4694000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	664000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1366000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6060000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	664000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	1113000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20243509	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14530126	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88533000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	82677000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88005000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73690000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	530000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8988000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6590000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9652000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4107000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2496000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11001000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14367000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	15108000	usd
	us-gaap	Operating Expenses OperatingExpenses	16863000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-15108000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16863000	usd
CY2022	us-gaap	Other Income OtherIncome	-74000	usd
	us-gaap	Other Income OtherIncome	-55000	usd
CY2022	us-gaap	Interest Expense InterestExpense	7000	usd
	us-gaap	Interest Expense InterestExpense	7000	usd
CY2022	crkn	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	1023000	usd
CY2022	crkn	Change In Fair Value Of Notes1 ChangeInFairValueOfNotes1	-149000	usd
	crkn	Gain On Extinguishment Of Debt1 GainOnExtinguishmentOfDebt1	7000	usd
	crkn	Gain On Forgiveness Of Ppp Loans GainOnForgivenessOfPPPLoans	-431000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	793000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	376000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14315000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16487000	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	55000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14370000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16487000	usd
CY2022	us-gaap	Basic Earnings Per Share Adjustment Pro Forma BasicEarningsPerShareAdjustmentProForma	-0.82
	us-gaap	Basic Earnings Per Share Adjustment Pro Forma BasicEarningsPerShareAdjustmentProForma	-1.13
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17436174	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14596019	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	16587000	usd
	crkn	Issuance Of Common Stock Warrants In Connection With Note Exchange Agreements IssuanceOfCommonStockWarrantsInConnectionWithNoteExchangeAgreements	244000	usd
	crkn	Stock Issued During The Period Stock Option Exercise StockIssuedDuringThePeriodStockOptionExercise	186000	usd
	crkn	Stockbased Compensation StockbasedCompensation	8458000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16487000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8988000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	855000	usd
CY2022	crkn	Issuance Of Common Stock Warrants In Connection With Sloc IssuanceOfCommonStockWarrantsInConnectionWithSLOC	223000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	1039000	usd
CY2022	crkn	Stock Issue Duringperiod Value Issuance Of Common Stock Atthemarket Offering Net Of Offering Costs StockIssueDuringperiodValueIssuanceOfCommonStockAtthemarketOfferingNetOfOfferingCosts	1249000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	86000	usd
CY2022	crkn	Stockbased Compensation StockbasedCompensation	2405000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14315000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	530000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14315000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16487000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2405000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8458000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	244000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	503000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	225000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	7000	usd
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	431000	usd
CY2022	crkn	Chang In Fair Value Of Derivative Liability ChangInFairValueOfDerivativeLiability	1023000	usd
CY2022	crkn	Change In Fair Value Of Notes ChangeInFairValueOfNotes	-149000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-52000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	73000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	494000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-182000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	500000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	413000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-126000	usd
CY2022	crkn	Increase Decrease In Accrued Interest IncreaseDecreaseInAccruedInterest	323000	usd
	crkn	Increase Decrease In Accrued Interest IncreaseDecreaseInAccruedInterest	87000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-396000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11140000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8537000	usd
CY2022	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	751000	usd
	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	552000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	61000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	264000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-812000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-816000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	855000	usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	1295000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	46000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3500000	usd
CY2022	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	1039000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	186000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6643000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	186000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5309000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-9167000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6130000	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15297000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	821000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6130000	usd
CY2022	crkn	Issuance Of Common Stock Warrants In Connection With Sloc IssuanceOfCommonStockWarrantsInConnectionWithSLOC	223000	usd
CY2022	crkn	Issuance Of Common Stock Warrants In Connection With Consideration Payable IssuanceOfCommonStockWarrantsInConnectionWithConsiderationPayable	86000	usd
CY2022	crkn	Unpaid Equipment Included In Accounts Payable UnpaidEquipmentIncludedInAccountsPayable	94000	usd
	crkn	Unpaid Equipment Included In Accounts Payable UnpaidEquipmentIncludedInAccountsPayable	206000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	7000	usd
	us-gaap	Interest Paid Net InterestPaidNet	6000	usd
CY2022Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.0001
CY2022Q3	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	1250000	shares
CY2022Q3	crkn	Purchase Price Per Share PurchasePricePerShare	0.744
CY2022Q3	crkn	Offering Price Per Share OfferingPricePerShare	0.8
CY2022Q3	us-gaap	Repayments Of Debt RepaymentsOfDebt	855000	usd
CY2022Q3	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	70000	usd
CY2022Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	75000	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	62500	shares
CY2022	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	0.8
CY2022	crkn	Accumulated Deficit AccumulatedDeficit	88000000	usd
CY2022Q4	crkn	Working Capital WorkingCapital	3300000	usd
CY2022	crkn	Net Loss NetLoss	14300000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	11100000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	800000	usd
CY2022	us-gaap	Debt Instrument Sinking Fund Payment DebtInstrumentSinkingFundPayment	10000000	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	100000000	usd
CY2022Q1	crkn	Irrevocable Standby Letter Of Credit IrrevocableStandbyLetterOfCredit	10000000	usd
CY2022	crkn	Exceed Federally Insured Limits ExceedFederallyInsuredLimits	250000000	usd
CY2022	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	125000000	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	41385793	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20368398	shares
CY2022Q1	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.12	pure
CY2022Q1	us-gaap	Debt Instrument Term DebtInstrumentTerm	P2Y
CY2022Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	50000	shares
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	1000000	usd
CY2022Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	5000000	usd
CY2022Q4	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	5400000	usd
CY2022Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	21749402	shares
CY2022Q1	crkn	Aggregate Gross Proceed Percentage AggregateGrossProceedPercentage	0.03	pure
CY2022Q4	crkn	Placement Shares Amount PlacementSharesAmount	3500000	usd
CY2022Q4	crkn	Aggregate Gross Proceed Percentage AggregateGrossProceedPercentage	0.03	pure
CY2022Q4	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	3368146	shares
CY2022	crkn	Agreement Of Sales AgreementOfSales	1250000	usd
CY2022	us-gaap	Payments For Commissions PaymentsForCommissions	50000.00	usd
CY2022	crkn	Share Based Compensation Arrangement By Share Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	0.385
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of its senior secured convertible notes and warrants, and equity based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of Credit Risk and Off-balance Sheet Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed the standard federally insured limits totaling $250,000. The Company believes it is not exposed to significant credit risk due to the the adoption of new banking products that provide additional federal insurance with coverage up to $125 million per entity in the depository institutions in which the cash and cash equivalents are held. The Company has <span style="-sec-ix-hidden: hidden-fact-135"><span style="-sec-ix-hidden: hidden-fact-136">no</span></span> financial instruments with off-balance sheet risk of loss as of December 31, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p>
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14315000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16487000	usd
CY2022	crkn	Cumulative Dividends On Series D Preferred Stock CumulativeDividendsOnSeriesDPreferredStock	-55000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14370000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16487000	usd
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	17552451	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15669636	shares
CY2022	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	116278	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1073617	shares
CY2022	crkn	Denominator For Basic And Diluted Net Loss Per Share DenominatorForBasicAndDilutedNetLossPerShare	17436173	shares
	crkn	Denominator For Basic And Diluted Net Loss Per Share DenominatorForBasicAndDilutedNetLossPerShare	14596019	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.13
CY2022	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0	pure
CY2022	crkn	Lease Liabilities LeaseLiabilities	1800000	usd
CY2022	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1800000	usd
CY2022	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	300000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	142000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	397000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	71000	usd
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	86000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	63000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	133000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	590000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	687000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1654000	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	972000	usd
CY2022Q4	crkn	Finite Lived Intangible Assets Research License Gross FiniteLivedIntangibleAssetsResearchLicenseGross	375000	usd
CY2021Q4	crkn	Finite Lived Intangible Assets Research License Gross FiniteLivedIntangibleAssetsResearchLicenseGross	375000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2175000	usd
CY2022	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	300000	usd
CY2022	us-gaap	Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1	50000.00	usd
	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	100000	usd
CY2021Q3	crkn	Consideration Paid Amount ConsiderationPaidAmount	264000000	usd
CY2021Q3	us-gaap	Legal Fees LegalFees	38000000	usd
CY2022	us-gaap	Information Technology And Data Processing InformationTechnologyAndDataProcessing	375000000	usd
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2021Q1	crkn	Intellectual Property Agreement Description IntellectualPropertyAgreementDescription	the Company entered into the fourth amendment to the IP agreement with HP. Under the terms of the amendment, the parties agreed to amend the list of patent and patent applications, which includes two additional patents that are assignable to the Company by HP. The Company exercised the option to purchase the assignable patents and paid HP $1.55 million dollars on February 9, 2021. Upon assignment of the patents, the Company will pay HP a royalty fee based on the cumulative gross revenue received by the Company from the patents as follows:1. Prior to December 31, 2029: ●Less than $70,000,000, royalty rate of 0.00% ●$70,000,000 - $500,000,000, royalty rate of 1.25% ●$500,000,000 and beyond, royalty rate of 1.00% 2. After January 1, 2030 and onward, royalty rate of 0.00% Under the terms of the amendment, HP waived any interest that would have been accrued on the open payable of $75,000 which was due from the Company related to the license agreement dated January 31, 2016.
CY2022Q4	crkn	Finite Lived Intangible Assets Patents Gross FiniteLivedIntangibleAssetsPatentsGross	1800000	usd
CY2021Q4	crkn	Finite Lived Intangible Assets Patents Gross FiniteLivedIntangibleAssetsPatentsGross	1739000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2114000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	577000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	353000	usd
CY2022Q4	crkn	Finite Lived Intangible Assets Accumulated Research License Net FiniteLivedIntangibleAssetsAccumulatedResearchLicenseNet	1598000	usd
CY2021Q4	crkn	Finite Lived Intangible Assets Accumulated Research License Net FiniteLivedIntangibleAssetsAccumulatedResearchLicenseNet	1761000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	220000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	221000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	220000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	183000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	754000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1598000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	150000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	104	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	234	usd
CY2021Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	57	usd
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	510	usd
CY2022	us-gaap	Other Expenses OtherExpenses	7	usd
	us-gaap	Other Expenses OtherExpenses	7	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	621	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	298	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	5400000	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	21749402	shares
CY2022Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.54	pure
CY2022Q4	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.35	pure
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.49
CY2022	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.32
CY2022	us-gaap	Line Of Credit Facility Expiration Period LineOfCreditFacilityExpirationPeriod	P5Y
CY2022Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	1700000	usd
CY2021Q4	us-gaap	Loans And Leases Receivable Net Reported Amount LoansAndLeasesReceivableNetReportedAmount	430500000	usd
CY2020Q2	us-gaap	Payments For Loans PaymentsForLoans	8000000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.08	pure
CY2022	crkn	Underwriters Purchase UnderwritersPurchase	62500	usd
CY2022	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	0.8
CY2021	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	200000	usd
	crkn	Stock Issued During Period Value Stock Options Exercised1 StockIssuedDuringPeriodValueStockOptionsExercised1	200000	usd
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4200000	shares
CY2022	crkn	Total Number Of Outstanding Shares Percentage TotalNumberOfOutstandingSharesPercentage	0.199	pure
CY2022	crkn	Other Research And Development Expenses OtherResearchAndDevelopmentExpenses	508000	usd
	crkn	Other Research And Development Expenses OtherResearchAndDevelopmentExpenses	384000	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	1897000	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	8318000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2405000	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	8702000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1939683	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.4
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	676350	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.37
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	892016	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	2.09
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease	-1095237	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	4.5
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	628780	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2.3
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	300000	usd
CY2022	crkn	Recognized Weightedaverage Term RecognizedWeightedaverageTerm	P1Y
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	66666	shares
	crkn	Vested Restricted Stock Award VestedRestrictedStockAward	88888	shares
	crkn	Unvested Restricted Stock Awards UnvestedRestrictedStockAwards	711112	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	832500	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	300000	usd
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1442204	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	5100000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11135432	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.85
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	13031000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	832500	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.4
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	977638	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	3.2
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1476670	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.6
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9513624	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.64
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	26188000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8579370	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.8
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	26188000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	977638	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.2
CY2022	crkn	Stock Option Cancellations StockOptionCancellations	33332	shares
CY2022	crkn	Stock Options Were Canceled With Employee Departures StockOptionsWereCanceledWithEmployeeDepartures	944306	shares
CY2022	crkn	Vested Stock Option VestedStockOption	789527	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	21759402	shares
CY2022Q4	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.32
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q3	us-gaap	Retail Land Sales Installment Method Sales Value RetailLandSalesInstallmentMethodSalesValue	85450	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	as additional consideration for the PO’s, the Company issued a warrant to Hudson to purchase 300,000 shares of the Company’s common stock at $0.75 per share. The warrant has a five-year life and expires on August 12, 2027.
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	161700	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	85450	usd
CY2022	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	223000	usd
CY2022Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	73000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	150000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	34200000	usd
CY2022	us-gaap	Federal State And Local Income Tax Expense Benefit Continuing Operations FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations	24200000	usd
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	34200000	usd
CY2017Q4	us-gaap	Effective Income Tax Rate Reconciliation Tax Holidays EffectiveIncomeTaxRateReconciliationTaxHolidays	0.80	pure
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	26000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8438000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7229000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	923000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	986000	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	25000	usd
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	6000	usd
CY2022	crkn	Lease Liability LeaseLiability	409000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	707000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	78000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10580000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8223000	usd
CY2022	us-gaap	Depreciation Depreciation	46000	usd
CY2021	us-gaap	Depreciation Depreciation	46000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	388000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10146000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8177000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.001	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	-0.002	pure
	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	0.006	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.04	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.063	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.015	pure
CY2022	crkn	Deferred Tax Trueup Return To Provision DeferredTaxTrueupReturnToProvision	-0.046	pure
	crkn	Deferred Tax Trueup Return To Provision DeferredTaxTrueupReturnToProvision	0.087	pure
	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.008	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.138	pure
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.232	pure
CY2016Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400000	usd
CY2016Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1200000	usd
CY2017Q4	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1800000	usd
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4500000	usd
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	7550000	usd
CY2021Q3	crkn	Seventh Amendment Description SeventhAmendmentDescription	the Company entered into the seventh amendment to its lease with Oregon State University which expands the lease to now include approximately 703 square feet of lab space, 576 square feet of cubicle space, 1096 square feet of Highbay lab space, and 376 square feet of High bay storage space in a building commonly known as Building 11.
CY2021Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	31647000	usd
CY2022Q1	crkn	Eighth Amendmen Description EighthAmendmenDescription	the Company entered into the eighth amendment to its lease with Oregon State University which expands the lease to now include approximately 703 square feet of lab space, 768 square feet of cubicle space, 2,088 square feet of Highbay lab space, and 376 square feet of High bay storage space in a building commonly known as Building 11.
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	44252000	usd
CY2021Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021Q2	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	7388000	usd
CY2021Q2	us-gaap	Operating Leases Of Lessor Contingent Rentals Basis Spread On Variable Rate OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate	0.03	pure
CY2021Q2	us-gaap	Deposit Assets DepositAssets	8315000	usd
CY2021Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1900000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1800000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	760000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	50000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	810000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	719000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2336000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	776000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	678000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	475000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	390000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	58000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	2377000	usd
CY2022Q4	crkn	Operating Leases Future Minimum Payments Present Value Discount OperatingLeasesFutureMinimumPaymentsPresentValueDiscount	437000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1940000	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	800000	usd
	us-gaap	Payments For Rent PaymentsForRent	200000	usd
CY2022	crkn	Promissory Note Issued PromissoryNoteIssued	2000000	usd
CY2022Q4	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	0.5
CY2022	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	The warrant to purchase 45,000 shares of the Company’s Series E preferred stock is exercisable for five years at an exercise price of the greater of $0.50 per share multiplied by 1,000, and subject to adjustment under certain circumstances described in the warrant.
CY2022	crkn	Net Proceeds On Sales NetProceedsOnSales	12700100	shares
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	2110000	usd
CY2022	us-gaap	Leasing Commissions Expense LeasingCommissionsExpense	90000.00	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	0.189
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	6405844	shares
CY2022	crkn	Exercise Of Warrants ExerciseOfWarrants	6405844	shares
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2021Q4	us-gaap	Deferred Costs DeferredCosts		usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum		pure
CY2021Q4	crkn	Notes Payable At Fair Value NotesPayableAtFairValue		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	crkn	Series A Preferred Stock SeriesAPreferredStock		usd
CY2021Q4	crkn	Series A Preferred Stock SeriesAPreferredStock		usd
CY2022Q4	crkn	Series B Preferred Stock Value SeriesBPreferredStockValue		usd
CY2021Q4	crkn	Series B Preferred Stock Value SeriesBPreferredStockValue		usd
CY2022Q4	crkn	Series C Preferred Stock Value SeriesCPreferredStockValue		usd
CY2021Q4	crkn	Series C Preferred Stock Value SeriesCPreferredStockValue		usd
CY2022Q4	crkn	Series D Preferred Stock SeriesDPreferredStock		usd
CY2021Q4	crkn	Series D Preferred Stock SeriesDPreferredStock		usd
	crkn	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability		usd
	crkn	Change In Fair Value Of Notes1 ChangeInFairValueOfNotes1		usd
CY2022	crkn	Gain On Extinguishment Of Debt1 GainOnExtinguishmentOfDebt1		usd
CY2022	crkn	Gain On Forgiveness Of Ppp Loans GainOnForgivenessOfPPPLoans		usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14596019	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17436174	shares
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
	crkn	Chang In Fair Value Of Derivative Liability ChangInFairValueOfDerivativeLiability		usd
	crkn	Change In Fair Value Of Notes ChangeInFairValueOfNotes		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	crkn	Issuance Of Common Stock Warrants In Connection With Sloc IssuanceOfCommonStockWarrantsInConnectionWithSLOC		usd
	crkn	Issuance Of Common Stock Warrants In Connection With Consideration Payable IssuanceOfCommonStockWarrantsInConnectionWithConsiderationPayable		usd
	crkn	Cumulative Dividends On Series D Preferred Stock CumulativeDividendsOnSeriesDPreferredStock		usd
CY2022	us-gaap	Basic Earnings Per Share Pro Forma BasicEarningsPerShareProForma
	us-gaap	Basic Earnings Per Share Pro Forma BasicEarningsPerShareProForma
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue		usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue		usd
CY2022Q4	us-gaap	Off Balance Sheet Credit Loss Liability OffBalanceSheetCreditLossLiability		usd
CY2021Q4	us-gaap	Off Balance Sheet Credit Loss Liability OffBalanceSheetCreditLossLiability		usd
CY2021Q4	crkn	Hudson Warrant HudsonWarrant		usd
CY2022Q4	us-gaap	Accrued Rent Current AccruedRentCurrent		usd
CY2021Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum		pure
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2022	crkn	Aggregate Intrinsic Value Weighted Average Remaining Contractual Term Years Granted AggregateIntrinsicValueWeightedAverageRemainingContractualTermYearsGranted
CY2022	crkn	Weighted Average Remaining Contractual Term Years Canceled WeightedAverageRemainingContractualTermYearsCanceled
CY2022	crkn	Accruals And Other Temporary Differences AccrualsAndOtherTemporaryDifferences		usd
CY2021	crkn	Accruals And Other Temporary Differences AccrualsAndOtherTemporaryDifferences		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001761696
CY2022	dei	Trading Symbol TradingSymbol	CRKN

Files In Submission

Name	View Source	Status
crkn-20221231_cal.xml	Edgar Link	unprocessable
0001213900-23-025483-index-headers.html	Edgar Link	pending
0001213900-23-025483-index.html	Edgar Link	pending
0001213900-23-025483.txt	Edgar Link	pending
0001213900-23-025483-xbrl.zip	Edgar Link	pending
crkn-20221231.xsd	Edgar Link	pending
f10k2022ex21-1_crownelectro.htm	Edgar Link	pending
f10k2022ex31-1_crownelectro.htm	Edgar Link	pending
f10k2022ex31-2_crownelectro.htm	Edgar Link	pending
f10k2022ex32-1_crownelectro.htm	Edgar Link	pending
f10k2022ex32-2_crownelectro.htm	Edgar Link	pending
f10k2022_crownelectro.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
crkn-20221231_def.xml	Edgar Link	unprocessable
crkn-20221231_lab.xml	Edgar Link	unprocessable
crkn-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_crownelectro_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRKN
Crown Electrokinetics Corp. Stock $crkn

2023 Q1 Form 10-K Financial Statement

#000121390023025483 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRKN Crown Electrokinetics Corp. Stock $crkn

2023 Q1 Form 10-K Financial Statement

#000121390023025483 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRKN
Crown Electrokinetics Corp. Stock $crkn